Regulated expression of GRP78 during vasopressin-induced hypertrophy of heart-derived myocytes.
Although the development of cellular hypertrophy is widely believed to involve Ca(2+) signaling, potential supporting roles for sequestered Ca(2+) in this process have not been explored. H9c2 cardiomyocytes respond to arginine vasopressin with an initial mobilization of Ca(2+) stores and reduced rates of mRNA translation followed by repletion of Ca(2+) stores, up-regulation of translation beyond initial rates, and the development of hypertrophy. Rates of synthesis of the endoplasmic reticulum (ER) chaperones, GRP78 and GRP94, were found to increase preferentially at early times of vasopressin treatment. Total GRP78 content increased 2- to 3-fold within 8 h after which the chaperone was subject to post-translational modification. Preferential synthesis of GRP78 and the increase in chaperone content both occurred at pM vasopressin concentrations and were abolished at supraphysiologic Ca(2+) concentrations. Co-treatment with phorbol myristate acetate decreased vasopressin-dependent Ca(2+) mobilization and slowed appearance of new GRP78 molecules in response to the hormone, whereas 24 h pretreatment with phorbol ester prolonged vasopressin-dependent Ca(2+) mobilization and further increased rates of GRP78 synthesis in response to the hormone. Findings did not support a role for newly synthesized GRP78 in translational up-regulation by vasopressin. However up-regulation, which does not depend on Ca(2+) sequestration, appeared to expedite chaperone expression. This report provides the first evidence that a Ca(2+)-mobilizing hormone at physiologic concentrations signals increased expression of GRP78. Translational tolerance to depletion of ER Ca(2+) stores, typifying a robust ER stress response, did not accompany vasopressin-induced hypertrophy.
Brostrom
M A
MA
Department of Pharmacology, U.M.D.N.J.-Robert Wood Johnson Medical School, Piscataway, New Jersey 08854, USA. brostrom@umdnj.edu
Mourad
F
F
Brostrom
C O
CO
D000818:Animals; D018053:Arsenites / Q000494:pharmacology; D002118:Calcium / Q000378:metabolism*; D002352:Carrier Proteins / Q000096:biosynthesis*; D048429:Cell Size; D002999:Clone Cells / Q000166:cytology; D004721:Endoplasmic Reticulum / Q000378:metabolism*; D000091342:Endoplasmic Reticulum Chaperone BiP; D018840:HSP70 Heat-Shock Proteins / Q000096:biosynthesis*; D006360:Heat-Shock Proteins; D006984:Hypertrophy / Q000139:chemically induced / Q000378:metabolism; D015759:Ionomycin / Q000494:pharmacology; D008565:Membrane Proteins / Q000096:biosynthesis*; D018832:Molecular Chaperones / Q000096:biosynthesis* / Q000187:drug effects; D009206:Myocardium / Q000378:metabolism* / Q000473:pathology*; D010704:Phorbols / Q000494:pharmacology; D051381:Rats; D017670:Sodium Compounds / Q000494:pharmacology; D015854:Up-Regulation / Q000187:drug effects / Q000502:physiology; D014667:Vasopressins / Q000494:pharmacology
D018053:Arsenites; D002352:Carrier Proteins; D000091342:Endoplasmic Reticulum Chaperone BiP; D018840:HSP70 Heat-Shock Proteins; D006360:Heat-Shock Proteins; D008565:Membrane Proteins; D018832:Molecular Chaperones; D010704:Phorbols; D017670:Sodium Compounds; C018551:glucose-regulated proteins; D014667:Vasopressins; C017947:sodium arsenite; D015759:Ionomycin; D002118:Calcium